CA
NZ
UK
AU
IND
US
…
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Invivyd Inc. is a publicly listed biotechnology company; available public disclosures about its programs and corporate strategy are limited as of mid‑2024. Long‑term growth may depend on advancing development programs through clinical and regulatory milestones, securing partnerships or licensing, and executing commercialization if approvals are achieved, factors that could support upside for investors who monitor clinical progress closely.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -52.49M | -169.93M | -198.64M | -241.32M | -226.79M |
| Net income | -52.49M | -169.93M | -198.64M | -234.60M | -234.29M |
| Selling general administrative | 66.93M | 63.39M | 49.12M | 47.04M | 36.52M |
| Gross profit | 49.68M | 23.77M | -2.03M | - | - |
| Reconciled depreciation | 2.11M | 3.11M | 1.72M | 0.46M | 0.00M |
| Ebit | -52.49M | -169.93M | -207.78M | -248.03M | -226.91M |
| Ebitda | -50.38M | -166.81M | -205.75M | -204.49M | -211.91M |
| Depreciation and amortization | 2.11M | 3.11M | 2.03M | 43.55M | 15.00M |
| Non operating income net other | - | - | - | 6.71M | - |
| Operating income | -55.56M | -176.88M | -212.76M | -248.03M | -226.91M |
| Other operating expenses | 108.99M | 202.26M | 212.76M | 226.26M | 219.41M |
| Interest expense | - | - | - | 43.08M | 15.00M |
| Non recurring | - | - | - | 4.40M | - |
| Income tax expense | - | - | - | -6.71M | 7.50M |
| Total revenue | 53.43M | 25.38M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 105.24M | 200.64M | 212.76M | 226.26M | 219.41M |
| Cost of revenue | 3.75M | 1.62M | 2.03M | - | - |
| Total other income expense net | 3.07M | 6.95M | 14.12M | 6.71M | 0.12M |
| Net income from continuing ops | -52.49M | -169.93M | -169.56M | -241.32M | -226.79M |
| Net income applicable to common shares | - | - | - | -241.32M | -226.79M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 276.88M | 129.51M | 229.18M | 383.17M | 620.09M |
| Other current assets | -19.32M | 20.16M | 23.31M | 4.93M | 25.29M |
| Total liab | 35.34M | 61.98M | 51.71M | 27.20M | 62.07M |
| Total stockholder equity | 241.54M | 67.54M | 177.47M | 355.97M | 558.02M |
| Other current liab | 19.11M | 50.22M | 40.90M | 21.95M | 56.28M |
| Common stock | 0.03M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.03M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -954.48M | -901.99M | -732.07M | -533.43M | -292.11M |
| Other liab | - | - | - | 0.00M | 0.01M |
| Other assets | - | - | - | 0.19M | 3.30M |
| Cash | 226.69M | 69.35M | 200.64M | 92.08M | 542.22M |
| Total current liabilities | 34.16M | 61.98M | 50.29M | 25.03M | 62.06M |
| Net debt | -224.19M | -68.05M | -198.48M | -88.35M | -542.22M |
| Short term debt | 1.31M | 1.30M | 1.44M | 1.56M | - |
| Short long term debt total | 2.49M | 1.30M | 2.17M | 3.72M | - |
| Other stockholder equity | 1196.04M | 969.53M | 680.36M | 506.49M | 850.12M |
| Property plant equipment | - | - | - | 2.28M | 0.08M |
| Total current assets | 247.47M | 100.68M | 224.88M | 376.92M | 616.71M |
| Net tangible assets | - | - | - | 355.97M | 558.02M |
| Short term investments | - | - | 0.00M | 279.92M | 49.19M |
| Net receivables | 14.60M | 11.17M | 0.93M | 0.38M | 0.23M |
| Inventory | 25.50M | 25.91M | - | -0.38M | - |
| Accounts payable | 13.74M | 10.45M | 7.95M | 1.52M | 5.78M |
| Accumulated other comprehensive income | -0.04M | -0.01M | -0.01M | -0.27M | -0.01M |
| Common stock total equity | - | - | - | 0.01M | - |
| Retained earnings total equity | - | - | - | -533.43M | - |
| Non currrent assets other | 25.61M | 25.94M | 0.17M | 0.19M | 3.30M |
| Non current assets total | 29.42M | 28.83M | 4.30M | 6.25M | 3.38M |
| Capital lease obligations | 2.49M | 1.30M | 2.17M | 3.72M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.14M | 63.95M | -228.96M | -50.63M |
| Change to liabilities | - | - | - | -39.13M | -2.37M |
| Total cashflows from investing activities | -0.15M | -0.14M | 280.68M | -230.67M | -50.71M |
| Total cash from financing activities | 215.63M | 39.33M | 1.04M | 0.51M | 662.68M |
| Change to operating activities | - | - | - | -11.83M | 25.16M |
| Net income | -52.49M | -169.93M | -198.64M | -241.32M | -226.79M |
| Change in cash | 157.34M | -131.29M | 108.56M | -450.15M | 427.24M |
| Begin period cash flow | 69.35M | 200.64M | 92.08M | 542.22M | 114.99M |
| End period cash flow | 226.69M | 69.35M | 200.64M | 92.08M | 542.22M |
| Total cash from operating activities | -58.13M | -170.49M | -173.16M | -219.99M | -184.74M |
| Issuance of capital stock | 215.93M | 39.28M | 0.00M | 0.00M | 666.07M |
| Depreciation | 2.11M | 3.11M | 2.03M | 0.46M | 0.00M |
| Change to inventory | -0.37M | -24.89M | 0.00M | - | - |
| Change to account receivables | -3.34M | -10.91M | 0.00M | - | - |
| Sale purchase of stock | -0.63M | 0.22M | -0.00M | -0.00M | 0.00M |
| Other cashflows from financing activities | - | -0.60M | -0.15M | 0.27M | 331.78M |
| Change to netincome | - | - | - | 39.02M | 19.26M |
| Capital expenditures | 0.15M | 0.14M | 0.61M | 1.71M | 0.08M |
| Cash flows other operating | - | - | - | 23.42M | - |
| Cash and cash equivalents changes | - | - | - | -450.15M | - |
| Change in working capital | -19.69M | -23.47M | 5.89M | -16.13M | 22.79M |
| Stock based compensation | 11.64M | 19.79M | 18.68M | 21.65M | 17.76M |
| Other non cash items | 0.30M | 19.79M | -1.12M | 15.35M | 0.07M |
| Free cash flow | -58.29M | -170.63M | -173.78M | -221.69M | -184.82M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IVVD Invivyd Inc. |
-0.03 4.82% |
0.57 | - | 44.64 | 4.19 | 1.45 | 1.90 | 0.78 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
| Name | Title | Year Born |
|---|---|---|
| Mr. David Hering M.B.A. | CEO & Director | 1975 |
| Ms. Jill Andersen J.D. | Chief Legal Officer & Corp. Sec. | 1973 |
| Ms. Laura Walker Ph.D. | Co-Founder & Chief Scientific Officer | 1985 |
| Mr. Frederick W. Driscoll | Interim CFO, Principal Financial Officer & Principal Accounting Officer | 1951 |
| Dr. Rebecca Dabora Ph.D. | Chief Technology & Manufacturing Officer | 1959 |
| Kyra Rosow Faircloth | VP of Gov. Affairs, Advocacy & Corp. Communication | NA |
| Dr. Peter C. Schmidt M.D., M.Sc. | Chief Medical Officer | NA |
| Mr. David Hering M.B.A. | CEO & Director | 1976 |
| Ms. Jill Andersen J.D. | Chief Legal Officer & Corporate Secretary | 1973 |
| Mr. William E. Duke Jr., M.B.A. | Chief Financial Officer | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...